Dr. Rothman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2500 W. 12th St
The Regional Cancer Ctr
Erie, PA 16505Phone+1 814-838-9000Fax+1 814-838-0443
Education & Training
NYU Grossman Long Island School of MedicineFellowship, Hematology and Medical Oncology, 1988 - 1991
New York Downtown HospitalResidency, Internal Medicine, 1985 - 1988
University of Newcastle Upon Tyne Faculty of MedicineClass of 1984
Certifications & Licensure
NY State Medical License 1988 - 2026
PA State Medical License 1995 - 2024
NJ State Medical License 1991 - 1995- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Clinical Trials
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Publications & Presentations
PubMed
- Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.Stephen G Chun, Chen Hu, Ritsuko U Komaki, Robert D Timmerman, Steven E Schild
JAMA Oncology. 2024-08-01 - 43 citationsPemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508Suresh S. Ramalingam, Suzanne E. Dahlberg, Chandra P. Belani, Joel N. Saltzman, Nathan A. Pennell
Journal of Clinical Oncology. 2019-07-30 - 112 citationsAdjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trialHeather A. Wakelee, Suzanne E. Dahlberg, Steven M. Keller, William Tester, David R. Gandara
The Lancet. Oncology. 2017-12-01
Press Mentions
Debunking Scary Myths About CancerMay 16th, 2022- How UPMC Hamot Pioneered Use of New Technology to Detect Lung Cancer EarlyMarch 18th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
